NASDAQ$ANGO

AngioDynamics Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

AngioDynamics' Q3 2020 financial results were announced, showing a net sales increase of 6.5% compared to the prior-year quarter.

AngioDynamics reported a 6.5% increase in net sales for the third quarter of fiscal year 2020, reaching $69.8 million. The company's gross margin was 57.8%, a slight decrease of 40 basis points year over year. The company experienced a net loss from continuing operations of $5.7 million, or a loss of $0.15 per share, while adjusted earnings per share were $0.01. Due to the uncertainty created by the COVID-19 pandemic, management is withdrawing its fiscal year 2020 financial guidance.

  • Net sales increased 6.5% to $69.8 million compared to the prior-year quarter.
  • Gross margin declined 40 basis points to 57.8% year over year.
  • GAAP loss per share was $0.15, with adjusted earnings per share at $0.01.
  • PATHFINDER I Registry was launched to evaluate the AURYON™ Atherectomy System's performance.
  • Fiscal year 2020 financial guidance was withdrawn due to COVID-19 pandemic uncertainty.

Headline financials

Total Revenue

$69.8M

Previous: $86.3M-19.2%
EPS (adj)

$0.01

Previous: $0.19-94.7%
Gross Margin

57.8%

Previous: 58.2%-0.7%
Capital Expenditures

-$5.76M

Previous: -$2.3M-149.9%
Free Cash Flow

-$11.5M

Previous: -$1.51M-660.8%
Net Income

-$5.71M

Previous: $796K-817.2%
Operating Income

-$6.24M

Previous: $2.79M-323.8%
Gross Profit

$40.3M

Previous: $46.7M-13.7%
Cash & Equivalents

$27.2M

Previous: $41.7M-34.9%
Total Assets

$732M

Previous: $778M-5.9%
Stock-Based Comp

$1.77M

Previous: $2.38M-25.5%

Revenue & EPS history

AngioDynamics · Revenue · Quarterly

$69.8M

Q3 2020-19.2%vs Q3 2019
Beat estimate in 9 of 16 quarters(56%)
ActualEstimate

Revenue by segment

AngioDynamics · $78.7M total across 2 segments · Q1 2024

  • Med Device
    $52.8M-10.0%
  • Med Tech
    $25.9M+13.4%

Forward guidance

Due to the ongoing pandemic, health systems are prioritizing the care of COVID-19 patients, impacting certain procedures and creating uncertainty, leading management to withdraw its fiscal year 2020 financial guidance.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

-0.9%

Avg return

Earnings day

-2.4%

Avg return

5 days after

-3.7%

Avg return

30 days after

43%

28 / 65 earnings

Positive

+30.9%

Q2 2025

Best reaction

-26.2%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026+5.0%-5.0%
Q2 2026-13.5%-25.5%-24.0%
Q1 2026+6.1%-0.2%+8.7%
Q4 2025-10.2%-9.8%-9.3%
Q3 2025+12.4%-3.6%-3.8%
Q2 2025+30.9%+32.6%+17.4%
Q1 2025-20.3%-23.1%-12.7%
Q4 2024+24.8%+21.1%+25.8%
Q3 2024+15.6%+14.6%+3.1%
Q2 2024-17.7%-20.1%-23.5%
Q1 2024-5.9%-7.2%-10.4%
Q4 2023-2.5%-3.8%-16.1%
Q3 2023-17.1%-23.3%-33.3%
Q2 2023+11.5%-1.0%-1.3%
Q1 2023-26.2%-38.0%-34.8%
Q4 2022+4.4%+6.4%+21.3%
Q3 2022+9.8%+7.2%-8.7%
Q2 2022-15.5%-15.5%-25.8%
Q1 2022+12.6%+17.8%+22.4%
Q4 2021-7.0%-8.6%-3.9%
Q3 2021+12.3%+11.1%+16.3%
Q2 2021+14.7%+14.2%+24.7%
Q1 2021+13.0%+7.8%-0.1%
Q4 2020-11.5%-11.8%-12.7%
Q3 2020-2.7%+2.3%-0.6%
Q2 2020-9.2%-11.3%-17.0%
Q1 2020-17.6%-17.6%-13.7%
Q4 2019+6.8%+6.2%-4.8%
Q3 2019-7.7%-8.2%-18.4%
Q2 2019+6.7%+6.7%+8.6%
Q1 2019-10.3%-12.9%-17.0%
Q4 2018-9.2%-7.8%-5.4%
Q3 2018+3.2%+8.9%+16.4%
Q2 2018-1.8%-0.1%+5.1%
Q1 2018-8.9%-9.1%-8.4%
Q4 2017-5.9%-3.5%+5.1%
Q3 2017+0.3%-1.3%-10.2%
Q2 2017+1.7%+3.2%-2.5%
Q1 2017-4.5%-0.1%-8.4%
Q4 2016+10.6%+14.1%+8.4%
Q3 2016-2.1%
Q2 2016-8.7%
Q1 2016-8.8%
Q4 2015-2.3%
Q3 2015-6.1%
Q2 2015-0.9%
Q1 2015+3.8%
Q4 2014-5.0%
Q3 2014-1.5%
Q2 2014+6.1%
Q1 2014+5.3%
Q4 2013+1.3%
Q3 2013-7.4%
Q2 2013-2.4%
Q1 2013-8.8%
Q4 2010-0.9%
Q4 2012+4.0%
Q3 2011-1.3%
Q3 2012-1.3%
Q2 2012-5.7%
Q2 2011-5.7%
Q1 2011+3.5%
Q4 2011+3.5%
Q1 2012+3.5%
Q3 2010+0.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro